Last reviewed · How we verify

Bupivocaine

The University of The West Indies · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

Bupivocaine is a Small molecule drug developed by The University of The West Indies. It is currently FDA-approved. Also known as: Marcaine, marcaine.

Bupivacaine is a local anesthetic used in various medical procedures, including laparoscopic cholecystectomy, and has been studied for conditions such as gall stones, spinal stenosis, and spondylolisthesis. It is administered through different techniques, including intraperitoneal injection and regional nerve blocks, such as the Type 2/posterior Quadratus Lumborum block.

At a glance

Generic nameBupivocaine
Also known asMarcaine, marcaine
SponsorThe University of The West Indies
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivocaine

What is Bupivocaine?

Bupivocaine is a Small molecule drug developed by The University of The West Indies.

Who makes Bupivocaine?

Bupivocaine is developed and marketed by The University of The West Indies (see full The University of The West Indies pipeline at /company/the-university-of-the-west-indies).

Is Bupivocaine also known as anything else?

Bupivocaine is also known as Marcaine, marcaine.

What development phase is Bupivocaine in?

Bupivocaine is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing